Anti-Human/Mouse/Rat Activin A - 100 µg

ICC, IHC FFPE, N, WB

Activin A

Next Day Ambient

Activin A is a member of the TGF beta super family. It was originally identified and isolated because it stimulates the release of follicle-stimulating hormone (FSH). Activins are structurally related to inhibins, they share common beta subunits, but they exhibit opposite biological activities. Activins are homodimers of beta subunits and inhibins are heterodimers of an alpha subunit and a beta subunit. Since the initial discovery of Activin A, it has been shown to regulate cell differentiation, nerve cell survival, bone growth promotion, cell proliferation, and apoptosis. Activin A expression has been detected in prostate cancer, colon cancer and breast cancer. Because Activin A is able to inhibit cell proliferation by modulating the Rb pathway, it is thought to inhibit cancer development. This may not be the only mechanism by which activin may play a preventative role in cancer development. Activin has also been shown to increase the expression of a protein whose decreased expression is correlated with increased metastatic capacity. In addition, activin has an inhibitory effect on endothelial cell growth and can thereby block angiogenesis, preventing tumor growth and metastasis. The activin/inhibin nomenclature reflects the subunit composition of the proteins: activin A (βA - βA), activin B (βB - βB), activin AB (βA - βB), inhibin A (α - βA) and inhibin B (α - βB). At present, little is known about the contribution of the other β subunits to activin or inhibin formation and biology. At the amino acid sequence level, the mature human βA subunit is 100% identical to mouse βA, while the human and mouse α subunits share approximately 80% identity. Similarly to other TGF-β family members, activins exert their biological activities through binding to the heterodimeric complex composed of two membrane spanning serine-threonine kinases designated type I and type II. Two forms of activin receptor type I (Act RI-A and Act RI-B) and two forms of activin receptor type II (Act RII-A and Act RII-B) have been identified. Activin binds directly to Act RII, the complex then associates with Act RI and initiates signaling.

IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 5 µg/ml for 5-15 µm thick sections. The recommended secondary antibody for IHC is PN:G505. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
Neutralization: This antibody is useful for neutralization of Human Activin A bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human Activin A (at 7.5 ng/ml) is 2-6 µg/ml.
Immunocytochemistry: Suitable for use at concentration of 5-25 µg/mL.

Goat Anti-Human Activin A recognizes Human Activin A. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Purified Recombinant Human/Mouse/Rat Activin A (> 98%)

Polyclonal Antibody, Activin A, Human/Mouse/Rat Activin A, Anti-Human/Mouse/Rat Activin A, Activin A